Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01059552

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — NSCLC  

Locally Advanced Non-small Cell Lung Cancer Clinical Trial

Official title:
Phase I Study of the HDAC Inhibitor Vorinostat With Chemotherapy and Radiation Therapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Summary

The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.

Clinical Trial Description

This phase I trial will escalate doses of the histone deacetylase inhibitor (HDAC) vorinostat to a chemoradiation platform for cisplatin, pemetrexed and radiation to a dose of 70Gy in NSCLC patients with unresectable IIIA and dry IIIB disease. The endpoint will be to determine MTD of the combination. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01059552
Study type Interventional
Source Fox Chase Cancer Center
Contact
Status Completed
Phase Phase 1
Start date December 16, 2009
Completion date October 21, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT00702975 - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Phase 2
Recruiting NCT05339568 - Patient's Whole Process Follow-up Management(HOPE-1)
Recruiting NCT04749394 - A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy Phase 2
Recruiting NCT06287320 - The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer
Completed NCT01537991 - ISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I/II I-START Trial N/A
Completed NCT04648033 - Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC Phase 1
Not yet recruiting NCT04153734 - Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC Phase 2
Completed NCT03371550 - A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy Phase 2
Terminated NCT00614484 - Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer Phase 1/Phase 2
Not yet recruiting NCT05620199 - Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy N/A
Withdrawn NCT05481775 - Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer Phase 2